Millicore

Millicore is a fictional biotechnology company used in this article to illustrate a typical enterprise in the metabolic engineering and synthetic biology field. It is portrayed as a mid-sized firm focused on enabling sustainable production of chemicals and materials through engineered microorganisms. The company is depicted as headquartered in Cambridge, Massachusetts, with research facilities in North America and Europe, and it was founded in 2010 by scientists and industry executives.

Technology and approach: Millicore's platform integrates computational pathway design, genome editing, high-throughput screening, and adaptive laboratory evolution. The design-build-run workflow is intended to improve yields, titers, and production rates in microbial hosts such as E. coli and yeast. The firm offers in-house R&D services and a software suite used for metabolic modeling and strain design.

Products and services: Millicore provides strain design, process optimization, scale-up support, and access to its Millicore Design Suite. It engages in collaborations and contract research with pharmaceutical, chemical, and materials companies, as well as joint development agreements to advance early-stage projects.

History and status: In this fictional profile, Millicore has grown through multiple funding rounds and established partnerships with academic institutions and industry players while remaining privately held and privately funded.